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The −308G/A SNP of tumor necrosis factor-alpha (TNF-𝛼) gene affects TNF-𝛼 production. As its impact on transplant outcome
remains open to debate, we decided to genotype it in a cohort of transplant subjects. A retrospective analysis of 439 first kidney
recipients randomly divided into two subgroups (discovery and validation cohorts) was performed to identify the best predictors
of acute rejection (AR). The effect on transplant outcome was analyzed by an adjusted logistic regression model. Carriers of the A
allele, associatedwith elevated TNF-𝛼 production, presented a higher risk of AR (OR= 2.78; 95%CI = 1.40–5.51). Logistic regression
analyses for AR showed an interaction between the polymorphism and treatment with thymoglobulin (p-interaction = 0.03). In
recipients who did not receive thymoglobulin, carriers of A allele had higher risk of AR (OR = 4.05; 95% CI = 1.76–9.28). Moreover,
carriers of A allele not treated with thymoglobulin presented higher risk of AR than those who received thymoglobulin (OR = 13.74;
95% CI = 1.59–118.7). The AUC of the model in the discovery cohort was 0.70 and in the validation cohort was 0.69. Our findings
indicate that the −308G/A TNF-𝛼 polymorphism is associated with AR risk and it modulates the effectiveness of thymoglobulin
treatment. This pharmacogenetic effect lets us propose this SNP as a useful predictor biomarker to tailor immunosuppressive
regimens.
1. Introduction
Acute rejection after kidney transplantation is a major cause
of allograft dysfunction and can lead to rapid loss of graft
function despite antirejection therapy. Even after initial
recovery of kidney function, acute rejection is associatedwith
an increased risk of long-term graft failure [1]. The identi-
fication of variables that can trigger rejection or modulate
its severity could enable us to improve long-term allograft
survival. The variables identified to date include younger age
and African American ethnicity in the recipient, older donor
age, the degree of donor-recipient human leukocyte antigen
(HLA) mismatch, pretransplant anti-HLA alloantibodies,
panel-reactive antibodies, ischemia-reperfusion injury (e.g.,
manifested by delayed graft function), and the adequacy of
baseline immunosuppression [2]. It remains unknown why
variations in the incidence of acute rejection are observed
in patients with similar matching status who have received
identical immunosuppressive protocols [3]. Much evidence
exists to support the role of cytokines in the inflammatory
and immune responses that mediate allograft rejection [4–6].
Tumor necrosis factor-alpha (TNF-𝛼) is a proinflammatory
cytokine produced by monocytes/macrophages and, to a
lesser extent, by T cells and B cells [7, 8]. TNF-𝛼 is released
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Figure 1: Flow-chart: kidney recipients.
at the site of inflammation, where it causes endothelial cell
activation, upregulation of cell adhesionmolecules andMHC
expression, and increased vasodilatation and vascular perme-
ability [9].Therefore, TNF-𝛼 helps tomaintain the inflamma-
tory response to the allograft by facilitating recruitment and
activation of leukocytes.
Many researchers have reported increased serum concen-
trations of TNF-𝛼 during acute rejection of liver [10], heart
[11], and kidney [12, 13] allografts. The impact of TNF-𝛼 has
been also reported in human renal allograft biopsies and in
rat models of acute and chronic rejection [14, 15].
On the other hand, polymorphism in cytokine genes
could explain differences in cytokine production and, there-
fore, in severity of rejection between individuals [16–18].
Polymorphism associated with cytokine production has been
described in the gene encoding TNF-𝛼 [19]. The TNF-𝛼 gene
is located in HLA class III region of the major histocompat-
ibility complex (MHC) on chromosome 6p21.3 [15]. G-to-
A single-nucleotide polymorphism (SNP) at position −308
in the TNF-𝛼 promoter region results in two forms related
to their production, carriers of allele A, and GG genotype
[20]. The presence of allele A is associated with increased
transcriptional activity [19, 21] and elevated TNF-𝛼 produc-
tion [22].
As local TNF-𝛼 release promotes endothelial cell acti-
vation and intragraft leukocyte migration, increased pro-
duction of TNF-𝛼 could trigger rejection [10, 23, 24]. Con-
sequently, the role of TNF-𝛼 polymorphism in acute graft
rejection has been studied. Nonetheless, findings for the
association between TNF-𝛼 and rejection are inconsistent.
Some authors report that kidney recipients with the high-
producing TNF-𝛼−308A allele are at greater risk of rejection
[16, 18, 22, 24–31], whereas other authors foundno association
[32–38]. Given the apparently controversial results of the
studies performed to date, we investigated the impact of this
polymorphism in a large cohort of well-characterized kidney
recipients and validated our findings in a second cohort.
2. Subjects and Methods
2.1. Patients and Data Collection. Between January 2005 and
December 2012, a total of 623 Caucasian adult patients (≥18
years) received a deceased donor organ and were followed up
for at least 24 months in our center. We excluded 184 patients
(Figure 1). The data recorded were as follows: demographic
characteristics (recipient and donor), number of mismatches,
immunosuppressive treatment, immediate or delayed graft
function (need for dialysis in the first week after transplant),
and type of donor (brain death or circulatory death). All
diagnoses of rejection were confirmed by biopsy, and acute
rejection was categorized according to the Banff classification
[39]. Graft loss was defined as returning to chronic dialysis
or death with a functioning graft. The clinical and research
activities being reported are consistent with the Principles of
the Declaration of Istanbul, as outlined in the Declaration of
Istanbul on Organ Trafficking and Transplant Tourism. The
protocol was approved by the Local Ethics Committee, and
written informed consent was obtained from all patients.
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2.2. Histopathology and C4d Staining. An ultrasound-guided
graft biopsy was performed when clinically indicated, that
is, in patients with elevated serum creatinine levels. All
patients with delayed graft function underwent protocol
biopsy every 7 days until kidney function began to improve.
A representative biopsy involved at least 1 artery and more
than 7 glomeruli. All Banff-scored lesions were assessed [39].
Deposition of C4d was studied by immunohistochemistry.
Each patient with an acute rejection episode was tested for
serum alloantibody. We classified acute rejection as follows:
acute T cell rejection without vascular lesions, acute T
cell rejection with vascular lesions, and antibody-mediated
rejection according to the Banff classification [39, 40].
2.3. Immunosuppression. Patients who received a kidney
from a brain dead donorwere treatedmainly with tacrolimus,
mycophenolate mofetil, and methylprednisolone; when the
donors had expanded criteria or when ischemia time was
long, they also received basiliximab or thymoglobulin.
When the organ was donated after circulatory death, most
patients received treatment with tacrolimus, mycophenolate
mofetil, and methylprednisolone combined with basiliximab
or thymoglobulin. In patients who received thymoglobulin,
tacrolimus was introduced between days 4 and 6 after
transplant.
2.4. Cytokine Polymorphism Genotyping. Genomic DNA
was extracted from EDTA-anticoagulated peripheral whole
blood. The −308G/A TNF-𝛼 polymorphism (rs1800629) was
genotyped in a 7900HT Fast Real-Time PCR System using
a TaqMan assay (C 7514879 10, Applied Biosystems, Foster
City, California,USA), as recommendedby themanufacturer.
2.5. Statistical Analysis. Sample size was calculated based on
an alpha risk of 0.05 and a beta risk of 0.2 in a 2-tailed
contrast to detect a minimum relative risk of 2, assuming that
20% of patients not exposed to treatment would experience
vascular rejection. It was calculated that 57 patients would
be necessary in the high-producing group and 285 in the
non-high-producing group (STATA, version 12.0). Kidney
transplant recipients were randomly divided into two groups
(2/3 and 1/3). The study of predictive factors was performed
in 286 patients (discovery cohort) and subsequently validated
in 153 patients (validation cohort). The influence of cytokine
genotypes on acute rejection was expressed as a dichoto-
mous variable, namely, low producers (GG) or high and
intermediate producers (AA and GA). Qualitative variables
were compared using the chi-square test or Fisher exact
test and expressed as frequency distributions. Qualitative
variables are expressed as mean (SD) or median (IQR) in
the case of nonnormally distributed variables. They were
compared using the 𝑡-test or nonparametric tests where nec-
essary. An adjusted logistic regressionmodel was constructed
and included variables with 𝑝 < 0.15 in the univariate
analysis or variables that were biologically relevant in the
population analysis. Interactions with TNF-𝛼 polymorphism
were evaluated. The 𝑝 value for the interaction was obtained
from the models constructed. The adjusted odds ratios (Adj.
OR) are presented with their 95% confidence intervals.
Discriminatory power was evaluated using area under the
receiver operating characteristic (ROC) curves (AUC) of the
predicted probabilities obtained in the model. Calibration
was assessed using the Hosmer-Lemeshow goodness-of-fit
test in both the discovery cohort and the validation cohort.
Survival of the kidney transplants as functioning organs was
analyzed using theKaplan-Meiermethodwith a log-rank test.
Null hypotheses with an alpha error < 0.05were rejected.The
statistical package used was SPSS version 15.0.
3. Results
Of the total 439 patients in the cohort, 119 (27.1%) devel-
oped acute rejection (AR); of these, 83 experienced vascular
involvement (18.9%). Median follow-up was 62.5 (39.9–87.2)
months. The median time to rejection was 9 (7–15) days,
and 96.6% of all rejections were during the first year after
transplantation.The genotype distribution of −308A/G TNF-
𝛼 was 82.9% (𝑁 = 364) for GG, 15.3% (𝑁 = 67) for GA, and
1.8% (𝑁 = 8) for AA.
The study of predictive factors was performed in 286
patients and subsequently validated in 153 patients. The
distribution of risk factors was similar between the two
cohorts (Table 1). The results of the univariate analysis for
AR in the discovery cohort are shown in Table 2. The
variables significantly associated with a greater risk were age
(donor and recipient), the −308A/G polymorphism, and the
immunosuppressive treatment. Carriers of the A allele had
a greater risk of AR than patients with the GG genotype
(Table 2).
The model was adjusted to evaluate the development of
acute cellular rejection and only the statistically significant
variables were shown (Table 3). In this multivariate analysis,
a significant interaction was recorded between induction
treatment with thymoglobulin and the polymorphism in
TNF-𝛼 (𝑝 = 0.03) (Table 3). Carriers of the A allele who
were not treated with thymoglobulin had a 4.05 times greater
risk of vascular rejection than those harboring GG (Table 3)
(Figure 2). Furthermore, in the subgroup of carriers of A
allele, the probability of rejectionwas considerably higher (13-
fold) in patients not receiving thymoglobulin than in those
receiving thymoglobulin (Table 3). The area under the ROC
curve of the model in the discovery cohort was 0.70 (95% CI
= 0.62–0.78); the 𝑝 value of the Hosmer-Lemeshow test was
0.916. The model was subsequently applied in the validation
cohort, and the area under the ROC curve was 0.69 (95% CI
= 0.54–0.76).
4. Discussion
Alloimmune responses and differences in susceptibility to
rejection may be influenced by individual variations in
cytokine genes. Indeed, cytokine gene polymorphism types
have been extensively explored in transplantation because
they are thought to explain the heterogeneous outcomes of
the allograft and can thus help clinicians to tailor immuno-
suppression [5, 31, 33, 41–43].
Several studies have assessed the association between
the −308A/G TNF-𝛼 polymorphism and acute rejection
4 Journal of Immunology Research
Table 1: Characteristics of the two randomly divided cohorts of kidney recipients.
Discovery cohort (𝑛 = 286) Validation cohort (𝑛 = 153) 𝑝 value
Recipient age, years, mean ± SD 52.2 ± 13.5 51.8 ± 13.0 0.78
Male recipient,𝑁 (%) 191 (66.8%) 100 (65.4%) 0.76
Time on dialysis, months 17.8 (7.1–31.2) 16.8 (6.1–26.9) 0.58
Cause of chronic renal failure,𝑁 (%) 0.08
Glomerulonephritis 86 (30.1%) 53 (34.6%)
Chronic tubulointerstitial nephropathy 31 (10.8%) 23 (15.0%)
Nephroangiosclerosis 22 (7.7%) 11 (7.2%)
Polycystic kidney disease 45 (15.3%) 21 (13.7%)
Diabetic nephropathy 42 (14.7%) 8 (5.2%)
Unknown cause 48 (16.8%) 32 (20.9%)
Others 12 (4.2%) 5 (3.3%)
Donor age, years, mean ± SD 43.0 ± 14.3 42.6 ± 14.1 0.73
Male donor,𝑁 (%) 209 (73.6%) 112 (74.2%) 0.90
Donor type,𝑁 (%) 0.65
Brain death 111 (38.8%) 56 (36.6%)
Circulatory death 175 (61.2%) 97 (61.2%)
Immunosuppressive treatment,𝑁 (%) 0.87
Thymoglobulin + FK + MMF + P 98 (34.3%) 54 (35.3%)
IL2R + FK + MMF + P 127 (44.4%) 69 (45.1%)
FK + MMF + P 54 (18.9%) 28 (18.3%)
CsA + MMF + P 2 (0.7%) 0 (0)
FK + SRL + P 1 (0.3%) 1 (0.7%)
Belatacept + MMF + P 4 (1.4%) 1 (0.7%)
Follow-up time, months (median [IQR]) 74.9 (53.8–99.5) 73.0 (50.2–97.5) 0.54
Delayed graft function,𝑁 (%) 143 (50.0%) 80 (52.3%) 0.65
HLA-A mismatch,𝑁 (%) 0.56
0 24 (8.4%) 17 (11.3%)
1 118 (41.4%) 64 (42.4%)
2 143 (50.2%) 70 (46.4 %)
HLA-B mismatch,𝑁 (%) 0.55
0 12 (4.2%) 4 (2.6%)
1 112 (39.3%) 66 (43.4%)
2 161 (56.5%) 82 (53.9%)
HLA-DR mismatch,𝑁 (%) 0.13
0 34 (11.9%) 18 (11.8%)
1 123 (43.2%) 80 (52.6%)
2 128 (44.9%) 54 (35.5%)
Acute total rejection,𝑁 (%) 80 (28.0%) 39 (25.5%) 0.58
Acute rejection Banff ≥ 2,𝑁 (%) 55 (19.2%) 28 (18.3%) 0.81
Acute humoral rejection,𝑁 (%) 20 (7.0%) 10 (6.5%) 0.86
Genotype frequency GA/AA TNF-𝛼 −308,𝑁 (%) 49 (17.1%) 26 (17.0%) 0.97
Graft loss,𝑁 (%) 49 (17.1%) 21 (13.7%) 0.35
FK: tacrolimus; MMF: mycophenolate; P: prednisone; IL2R: interleukin- (IL-) 2 receptor antagonist; CsA: cyclosporin A; SRL: sirolimus.
in kidney recipients of different populations; however, the
results are apparently inconsistent and inconclusive. Our data
support reports that found association of this SNP with a
higher incidence of acute rejection [16, 18, 22, 24–31]. In
their meta-analysis, Hu et al. [44] concluded that the TNF-
𝛼 high producers genotypes in the recipient were associated
with an increased risk of acute allograft rejection. In this
meta-analysis, authors recommended performing additional
studies with large sample size and better study designs.
Discrepancies in previously reported findings may be
due to a small size that compromised the statistical power
and heterogeneity of the studies. Only few reports included
cohorts of consecutive transplants performed over a specific
time period [16, 24, 33, 34, 37] and some even recruited
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Table 2: Univariate analysis for acute rejection in the discovery cohort (𝑛 = 286).
Acute rejection𝑁 (%) OR (95% CI) 𝑝 value
Recipient age 0.04
<60 years 43 (22.6%) 2.04 (1.02 to 4.17)
≥60 12 (12.5%) 1
Recipient sex 0.17
Male 41 (21.5%) 1.59 (0.81 to 3.03)
Female 14 (14.7%) 1
Donor age 0.05
<60 years 54 (20.6%) 5.88 (0.81 to 50.0)
≥60 1 (4.2%) 1
Donor sex 0.22
Male 44 (21.1%) 1.72 (0.83 to 3.70)
Female 11 (14.5%) 1
Time on dialysis 0.64
<15 months 24 (18.0%) 1
≥15 months 31 (20.3%) 1.15 (0.64 to 2.09)
Donor type 0.47
Brain death 19 (17.1%) 1
Circulatory death 36 (20.6%) 1.25 (0.68 to 2.32)
Delayed graft function 0.45
Yes 30 (21.0%) 1.25 (0.70 to 2.26)
No 25 (17.5%) 1
TNF-𝛼 −308 polymorphism 0.003
GG 38 (16.0%) 1
GA/AA 17 (34.6%) 2.78 (1.40 to 5.51)
Immunosuppressive treatment 0.003
Thymoglobulin + FK + MMF + P 8 (8.2%) 1
IL2R + FK + MMF + P 32 (25.2%) 3.74 (1.63 to 8.57)
Other (belatacept, SRL) 15 (24.2%) 3.55 (1.40 to 8.98)
HLA mismatch 0.75
<3 4 (22.2%) 1.20 (1.38 to 3.85)
≥3 51 (19.1%) 1
HLA-DR mismatch 0.22
≤1 34 (21.9%) 1
2 21 (16.2%) 0.69 (0.38 to 1.25)
HLA-A mismatch 0.86
≤1 28 (19.7%) 1
2 27 (18.9%) 0.95 (0.52 to 1.71)
HLA-B mismatch 0.56
≤1 22 (17.7%) 1
2 33 (20.5%) 1.20 (0.66 to 2.18)
FK: tacrolimus; MMF: mycophenolate; P: prednisone; IL2R: interleukin- (IL-) 2 receptor antagonist; SRL: sirolimus.
hyperimmunized and retransplanted patients [16, 26, 30,
31, 33, 34, 37]. Moreover, rejection was not histologically
confirmed in most studies and incidence of rejection also
varies considerably, ranging from 17% [16] to 63% [24]. In
addition, discrepancies in terms of the impact of the TNF-
𝛼 polymorphism in kidney rejection could also arise because
of differences in the immunosuppressive therapy used, as the
type of medication administered is not usually included. The
most common immunosuppressive agents are cyclosporine,
prednisone, and azathioprine or mycophenolate [16, 18, 24–
27, 29–34, 36–38]. Our results suggest that use of triple ther-
apy based on tacrolimus, mycophenolate, and corticosteroids
may not be sufficient to block release of TNF-𝛼 in patients
with the high producer genotype. TNF-𝛼 is mainly gener-
ated by monocytes and macrophages [45] and it has been
reported that the aforementioned triple therapy does not have
a clear effect in these cells [46–48]. However, antithymocyte
globulin promotes expansion of regulatory T cells [49], the
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Table 3: Multivariate analysis for acute rejection in the discovery
cohort (𝑛 = 286).
Variable OR (95% CI)∗ 𝑝 value
No thymoglobulin treatment
TNF-𝛼 −308 GG 1
TNF-𝛼 −308 GA/AA 4.05 (1.76 to 9.28) 0.001
Thymoglobulin treatment
TNF-𝛼 −308 GG 1
TNF-𝛼 −308 GA/AA 0.65 (0.12 to 3.69) 0.65
TNF-𝛼 −308 GG
Thymoglobulin treatment 1
No thymoglobulin treatment 2.72 (1.05 to 7.05) 0.04
TNF-𝛼 −308 GA/AA
Thymoglobulin treatment 1
No thymoglobulin treatment 13.74 (1.59 to 118.7) 0.02
Recipient age
≥60 years 1
<60 years 2.29 (1.10 to 4.78) 0.03
∗Adjusted for recipient sex, donor age and sex, HLA-DR mismatches, and
delayed graft function.



















Figure 2: Percentage of AR in renal transplant patients stratified
both −308G/A TNF-𝛼 gene polymorphism and treatment with
thymoglobulin.
main producers of interleukin-10, which in turn inhibits pro-
duction of TNF-𝛼 by macrophages [50]. Therefore, antithy-
mocyte globulin could help to control the immune response
in patients who produce high levels of TNF-𝛼.
Our study is limited by the fact that TNF-𝛼 genotyping
was not performed in the donor. Nevertheless, bearing in
mind that most TNF-𝛼 is produced by macrophages, we
think that more emphasis should be placed on the receptor
genotype.
Before a model can be relied upon to draw conclusions or
predict future outcomes, it is important to ensure that it is cor-
rectly specified; that is, the data do not conflict with assump-
tions made by themodel. Logistic regression is the most pop-
ular modeling approach for binary outcomes. The Hosmer-
Lemeshow testmakes it possible to compare goodness of fit by
comparing observed and predicted risks across subgroups in
a population. Prediction models allow clinicians to estimate
prognosis [51, 52] and are increasingly used in clinical
practice to guide decision-making [52]. Our study is the first
one that retrospectively analyzed a prospective cohort of first
transplants in patients with no preformed antibodies who
were randomly assigned to two cohorts, a discovery and a
validation cohort. We attempted to predict the risk of acute
rejection according to variables that can modify the effect
simultaneously (age, delayed graft failure, immunosuppres-
sion protocol, and the TNF-𝛼 polymorphism).
5. Conclusions
The TNF-𝛼 gene polymorphism that was previously associ-
ated with differential production of this cytokine is associated
with AR risk and modulates the effectiveness of thymoglob-
ulin treatment. Screening of this polymorphism will enable
us to predict those patients (carriers of A allele) more likely
to experience rejection and, therefore, require more intense
immunosuppressive therapy. Similarly, it will enable us to
identify patients with a potentially optimal response, who can
be treated with less potent immunosuppression.
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